Our AIM™ Platform focuses on designing multi-functional biological products by engaging the innate immune system for cancer immunotherapy. It selects tumor associated antigen antibodies for cancer targeting, receptors agonist antibodies for innate effector activation, and cytokines and other ™E factors for immune modulation to design multi-specific antibody fusion proteins, and evaluates them in terms of expression, target binding, in vitro and in vivo biological activities, as well as druggability.
SunHo Armed Innate-effector Multispecific Platform AIM™
Currently, we have developed several categories of our proprietary AIM™ Platform that allow us to explore the combination of innate immunity stimulators with different types and numbers of targets, which provide us with abundant flexibility and diversity of various types of ™E modulations for different clinical indications. Our preclinical product IAN0982 was developed based on the AIM™ Platform.